Skip to main content

Advertisement

Table 1 Patients’ characteristics (absolute number of patients, percentages, descriptive statistics as reported in BIKER; comparison between the three cohorts weighted by an inverse probability of treatment)

From: Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab

  Etanercept cohort Adalimumab cohort Tocilizumab cohort Etanercept versus adalimumaba Tocilizumab versus etanercepta Tocilizumab versus adalimumaba
n = 419 n = 236 n = 74 OR (95% CI); p value OR (95% CI); p value OR (95% CI); p value
Female, n (%) 332 (79.2%) 192 (81.4%) 51 (68.8%) 0.96 (0.57; 1.62); 0.88 0.63 (0.45; 0.89); 0.03 0.58 (0.48; 0.98); 0.04
Age at baseline, years, mean ± SD 10.5 ± 4.4 11.8 ± 4.0 12.9 ± 3.6 0.63 (−0.31; 1.57); 0.19 1.65 (−0.67; 3.96); 0.16 1.02 (−1.31; 3.34); 0.39
 Median (IQR) 11.1 (7.1–13.9) 12.7 (8.7– 15.0) 13.5 (11.2– 15.9)    
Disease duration at treatment start, mean ± SD 3.6 ± 3.3 5.8 ± 4.0 6.1 ± 3.5 0.40 (−0.17; 0.98); 0.17 1.13 (−0.05; 2.02); 0.07 0.73 (−0.21; 1.66); 0.13
 Median (IQR) 2.6 (1.1–5.1) 4.9 (2.4–8.4) 5.8 (2.9–8.8)    
JIA category n (%)
 RF+ PA 37 (8.8%) 23 (9.7%) 9 (12.2%) 1.45 (0.74; 2.83); 0.28 0.95 (0.60; 1.49); 0.81 2.18 (0.48; 9.85); 0.31
 RF- PA 224 (53.5%) 128 (54.2%) 47 (63.5%) (ref) (ref) (ref)
 ExOA 158 (37.7%) 85 (36.0%) 18 (24.3%) 3.17 (0.74; 13.60); 0.12 0.71 (0.22; 2.27); 0.57 0.75 (0.24; 2.41); 0.63
First biologic used 400 (95.5%) 110 (46.6%) 14 (18.9%) 0.54 (0.28; 1.03); 0.06 0.44 (0.16; 1.18); 0.10 0.81 (0.34; 1.96); 0.65
Co-med corticosteroids, n (%) 134 (32.0) 60 (25.4) 26 (35.1) 1.38 (0.96; 1.97) 1.15 (0.69; 1.94) 1.59 (091; 2.78)
Co-med MTX, n (%) 302 (72.1) 127 (53.8) 34 (45.9) 1.20 (0.76; 1.88); 0.44 0.76 (0.28; 2.06); 0.59 0.64 (0.24; 1.70); 0.37
JADAS10 (0–40), mean ± SD 13.8 ± 7.1 12.1 ± 7.6 15.1 ± 7.4 −0.41 (−2.30; 1.48); 0.67 −0.53 (−4.22; 3.17); 0.78 −0.12 (−3.84; 3.60); 0.95
 Median (IQR) 13.6 (8.8–19.0) 11.7 (6.1–17.5) 14.8 (9.2–20.1)    
CHAQ-DI (0–3), mean ± SD 0.59 ± 0.60 0.43 ± 0.58 0.63 ± 0.55 −0.04 (−0.19; 0.12); 0.64 −0.10 (−0.30; 0.11); 0.35 −0.06 (−0.29; 0.17); 0.60
 Median (IQR) 0.38 (0.13–0.88) 0.13 (0–0.623) 0.63 (0.19-1.0)    
Uveitis before start of biologic 23 (5.5%) 59 (25%) 0 3.41 (3.21; 4.45); 0.03 - -
  1. aAnalyses weighted by an inverse probability of treatment estimated by a generalized propensity score. beta regression coefficient for continuous variables, CI confidence interval, OR odds ratio for categorical variable, (ref) reference group, JIA juvenile idiopathic arthritis, RF rheumatoid factor, PA, polyarthritis, ExOA extended oligoarthritis, JADAS Juvenile Disease Activity Score, CHAQ-DI Childhood Health Assessment Questionnaire disability index